Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis
Roselie Achten, Daphne S. Bakker, Lieneke F.M. Ariëns, Amanda Lans, Judith L. Thijs, Jorien van der Schaft, Joke de Boer, Deepak M.W. Balak, Marlies de Graaf, Chantal van Luijk, Marjolein de Bruin‐Weller
Abstract
Funding Information: Patients included in this manuscript participated in the BioDay registry sponsored by Sanofi Genzyme.Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie ; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest.